Immune responses to infection with H5N1 influenza virus

Virus Research

Volumn 178, Issue 1, 2013, Pages 44-52

  Rimmelzwaan, Guus F ^a   Katz, Jacqueline M ^b  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES   (United States)

Author keywords

Immune response; Infection; Influenza A H5N1 virus

Indexed keywords

CROSS REACTING ANTIBODY; H5N1 CLADE 1 VACCINE; HEMAGGLUTININ; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; IMMUNOGLOBULIN M ANTIBODY; INFLUENZA VACCINE; NEUTRALIZING ANTIBODY; OSELTAMIVIR; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; AMINO ACID SEQUENCE; ANTIBODY BLOOD LEVEL; ANTIBODY DETECTION; ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; ANTIBODY TITER; ANTIGEN ANTIBODY REACTION; ARTICLE; ASYMPTOMATIC INFECTION; AVIAN INFLUENZA VIRUS; CELLULAR IMMUNITY; ENZYME LINKED IMMUNOSORBENT ASSAY; EXPERIMENTAL INFECTION; HEMAGGLUTINATION INHIBITION; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOTHERAPY; INFLUENZA A (H5N1); INFLUENZA VACCINATION; INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H5N1; MEMORY CELL; NONHUMAN; POINT MUTATION; PRIORITY JOURNAL; SEASONAL INFLUENZA; SEROPREVALENCE; VIRUS ATTACHMENT; VIRUS NEUTRALIZATION; VIRUS REPLICATION;

ANIMALIA; ORTHOMYXOVIRIDAE;

IMMUNE RESPONSE; INFECTION; INFLUENZA A H5N1 VIRUS;

ANIMALS; ANTIBODIES, VIRAL; HUMANS; IMMUNITY, CELLULAR; IMMUNITY, HUMORAL; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA, HUMAN;

EID: 84887626418     PISSN: 01681702     EISSN: 18727492     Source Type: Journal    
DOI: 10.1016/j.virusres.2013.05.011     Document Type: Article

References (103)

1. Abdel-Ghafar A.N., Chotpitayasunondh T., Gao Z., Hayden F.G., Nguyen D.H., de Jong M.D., Naghdaliyev A., Peiris J.S., Shindo N., Soeroso S., Uyeki T.M. Update on avian influenza A (H5N1) virus infection in humans. The New England Journal of Medicine 2008, 358(3):261-273. Writing Committee of the Second World Health Organization Consultation on Clinical Aspects of Human Infection with Avian Influenza A.V.
2. Baumgarth N., Herman O.C., Jager G.C., Brown L.E., Herzenberg L.A., Chen J. B-1 and B-2 cell-derived immunoglobulin M antibodies are nonredundant components of the protective response to influenza virus infection. The Journal of Experimental Medicine 2000, 192(2):271-280.
3. Beare A.S., Webster R.G. Replication of avian influenza viruses in humans. Archives of Virology 1991, 119(1/2):37-42.
4. Belser J.A., Szretter K.J., Katz J.M., Tumpey T.M. Use of animal models to understand the pandemic potential of highly pathogenic avian influenza viruses. Advances in Virus Research 2009, 73:55-97.
5. Bodewes R., Rimmelzwaan G.F., Osterhaus A.D.M.E. Animal models for the preclinical evaluation of candidate influenza vaccines. Expert Review of Vaccines 2010, 9:59-72.
6. Brooks W.A., Alamgir A.S., Sultana R., Islam M.S., Rahman M., Fry A.M., Shu B., Lindstrom S., Nahar K., Goswami D., Haider M.S., Nahar S., Butler E., Hancock K., Donis R.O., Davis C.T., Zaman R.U., Luby S.P., Uyeki T.M., Rahman M. Avian influenza virus A (H5N1), detected through routine surveillance, in child, Bangladesh. Emerging Infectious Diseases 2009, 15(8):1311-1313.
7. Buchy P., Vong S., Chu S., Garcia J.M., Hien T.T., Hien V.M., Channa M., Ha do Q., Chau N.V., Simmons C., Farrar J.J., Peiris M., de Jong M.D. Kinetics of neutralizing antibodies in patients naturally infected by H5N1 virus. PLoS ONE 2010, 5(5):e10864.
8. Burlington D.B., Clements M.L., Meiklejohn G., Phelan M., Murphy B.R. Hemagglutinin-specific antibody responses in immunoglobulin G, A, and M isotypes as measured by enzyme-linked immunosorbent assay after primary or secondary infection of humans with influenza A virus. Infection and Immunity 1983, 41(2):540-545.
9. Caton A.J., Brownlee G.G., Yewdell J.W., Gerhard W. The antigenic structure of the influenza virus A/PR/8/34 hemagglutinin (H1 subtype). Cell 1982, 31(2 Pt 1):417-427.
10. Cheng X., Eisenbraun M., Xu Q., Zhou H., Kulkarni D., Subbarao K., Kemble G., Jin H. H5N1 vaccine-specific B cell responses in ferrets primed with live attenuated seasonal influenza vaccines. PLoS ONE 2009, 4(2):e4436.
11. Cheng X., Wu C., He J., Lv X., Zhang S., Zhou L., Wang J., Deng R., Long Q., Wang X., Cheng J. Serologic and genetic characterization analyses of a highly pathogenic influenza virus (H5N1) isolated from an infected man in Shenzhen. Journal of Medical Virology 2008, 80(6):1058-1064.
12. Corti D., Suguitan A.L., Pinna D., Silacci C., Fernandez-Rodriguez B.M., Vanzetta F., Santos C., Luke C.J., Torres-Velez F.J., Temperton N.J., Weiss R.A., Sallusto F., Subbarao K., Lanzavecchia A. Heterosubtypic neutralizing antibodies are produced by individuals immunized with a seasonal influenza vaccine. The Journal of Clinical Investigation 2010, 120(5):1663-1673.
13. Couch R.B., Kasel J.A., Gerin J.L., Schulman J.L., Kilbourne E.D. Induction of partial immunity to influenza by a neuraminidase-specific vaccine. The Journal of Infectious Diseases 1974, 129(4):411-420.
14. Cusick M.F., Wang S., Eckels D.D. In vitro responses to avian influenza H5 by human CD4 T cells. Journal of Immunology 2009, 183(10):6432-6441.
15. de Jong M.D., Bach V.C., Phan T.Q., Vo M.H., Tran T.T., Nguyen B.H., Beld M., Le T.P., Truong H.K., Nguyen V.V., Tran T.H., Do Q.H., Farrar J. Fatal avian influenza A (H5N1) in a child presenting with diarrhea followed by coma. The New England Journal of Medicine 2005, 352(7):686-691.
16. de Jong M.D., Simmons C.P., Thanh T.T., Hien V.M., Smith G.J., Chau T.N., Hoang D.M., Chau N.V., Khanh T.H., Dong V.C., Qui P.T., Cam B.V., Ha do Q., Guan Y., Peiris J.S., Chinh N.T., Hien T.T., Farrar J. Fatal outcome of human influenza A (H5N1) is associated with high viral load and hypercytokinemia. Nature Medicine 2006, 12(10):1203-1207.
17. Ding H., Tsai C., Zhou F., Buchy P., Deubel V., Zhou P. Heterosubtypic antibody response elicited with seasonal influenza vaccine correlates partial protection against highly pathogenic H5N1 virus. PLoS ONE 2011, 6(3):e17821.
18. Droebner K., Haasbach E., Fuchs C., Weinzierl A.O., Stevanovic S., Buttner M., Planz O. Antibodies and CD4(+) T-cells mediate cross-protection against H5N1 influenza virus infection in mice after vaccination with a low pathogenic H5N2 strain. Vaccine 2008, 26(52):6965-6974.
19. Ekiert D.C., Bhabha G., Elsliger M.A., Friesen R.H., Jongeneelen M., Throsby M., Goudsmit J., Wilson I.A. Antibody recognition of a highly conserved influenza virus epitope. Science 2009, 324(5924):246-251.
20. Feng J.Q., Mozdzanowska K., Gerhard W. Complement component C1q enhances the biological activity of influenza virus hemagglutinin-specific antibodies depending on their fine antigen specificity and heavy-chain isotype. Journal of Virology 2002, 76(3):1369-1378.
21. Fornek J.L., Gillim-Ross L., Santos C., Carter V., Ward J.M., Cheng L.I., Proll S., Katze M.G., Subbarao K. A single-amino-acid substitution in a polymerase protein of an H5N1 influenza virus is associated with systemic infection and impaired T-cell activation in mice. Journal of Virology 2009, 83(21):11102-11115.
22. Garcia J.M., Pepin S., Lagarde N., Ma E.S., Vogel F.R., Chan K.H., Chiu S.S., Peiris J.S. Heterosubtype neutralizing responses to influenza A (H5N1) viruses are mediated by antibodies to virus haemagglutinin. PLoS ONE 2009, 4(11):e7918.
23. Gerhard W. The role of the antibody response in influenza virus infection. Current Topics in Microbiology and Immunology 2001, 260:171-190.
24. Gioia C., Castilletti C., Tempestilli M., Piacentini P., Bordi L., Chiappini R., Agrati C., Squarcione S., Ippolito G., Puro V., Capobianchi M.R., Poccia F. Cross-subtype immunity against avian influenza in persons recently vaccinated for influenza. Emerging Infectious Diseases 2008, 14(1):121-128.
25. Govorkova E.A., Ilyushina N.A., Boltz D.A., Douglas A., Yilmaz N., Webster R.G. Efficacy of oseltamivir therapy in ferrets inoculated with different clades of H5N1 influenza virus. Antimicrobial Agents and Chemotherapy 2007, 51(4):1414-1424.
26. Grandea A.G., Olsen O.A., Cox T.C., Renshaw M., Hammond P.W., Chan-Hui P.Y., Mitcham J.L., Cieplak W., Stewart S.M., Grantham M.L., Pekosz A., Kiso M., Shinya K., Hatta M., Kawaoka Y., Moyle M. Human antibodies reveal a protective epitope that is highly conserved among human and nonhuman influenza A viruses. Proceedings of the National Academy of Sciences of the United States of America 2010, 107(28):12658-12663.
27. Grebe K.M., Yewdell J.W., Bennink J.R. Heterosubtypic immunity to influenza A virus: where do we stand?. Microbes and Infection 2008, 10(9):1024-1029.
28. Hancock K., Veguilla V., Lu X., Zhong W., Butler E.N., Sun H., Liu F., Dong L., DeVos J.R., Gargiullo P.M., Brammer T.L., Cox N.J., Tumpey T.M., Katz J.M. Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus. The New England Journal of Medicine 2009, 361(20):1945-1952.
29. Hassantoufighi A., Zhang H., Sandbulte M., Gao J., Manischewitz J., King L., Golding H., Straight T.M., Eichelberger M.C. A practical influenza neutralization assay to simultaneously quantify hemagglutinin and neuraminidase-inhibiting antibody responses. Vaccine 2010, 28(3):790-797.
30. Hatta M., Gao P., Halfmann P., Kawaoka Y. Molecular basis for high virulence of Hong Kong H5N1 influenza A viruses. Science 2001, 293(5536):1840-1842.
31. Hatta Y., Hershberger K., Shinya K., Proll S.C., Dubielzig R.R., Hatta M., Katze M.G., Kawaoka Y., Suresh M. Viral replication rate regulates clinical outcome and CD8 T cell responses during highly pathogenic H5N1 influenza virus infection in mice. PLoS Pathogens 2010, 6(10):e1001139.
32. Herfst S., Schrauwen E.J., Linster M., Chutinimitkul S., de Wit E., Munster V.J., Sorrell E.M., Bestebroer T.M., Burke D.F., Smith D.J., Rimmelzwaan G.F., Osterhaus A.D., Fouchier R.A. Airborne transmission of influenza A/H5N1 virus between ferrets. Science 2012, 336(6088):1534-1541.
33. Hillaire M.L., Osterhaus A.D., Rimmelzwaan G.F. Induction of virus-specific cytotoxic T lymphocytes as a basis for the development of broadly protective influenza vaccines. Journal of Biomedicine and Biotechnology 2011, 939860.
34. Hillaire M.L., van Trierum S.E., Kreijtz J.H., Bodewes R., Geelhoed-Mieras M.M., Nieuwkoop N.J., Fouchier R.A., Kuiken T., Osterhaus A.D., Rimmelzwaan G.F. Cross-protective immunity against influenza pH1N1 2009 viruses induced by seasonal influenza A (H3N2) virus is mediated by virus-specific T-cells. The Journal of General Virology 2011, 92(Pt 10):2339-2349.
35. Hinshaw V.S., Webster R.G., Easterday B.C., Bean W.J. Replication of avian influenza A viruses in mammals. Infection and Immunity 1981, 34(2):354-361.
36. Hoffmann E., Lipatov A.S., Webby R.J., Govorkova E.A., Webster R.G. Role of specific hemagglutinin amino acids in the immunogenicity and protection of H5N1 influenza virus vaccines. Proceedings of the National Academy of Sciences of the United States of America 2005, 102(36):12915-12920.
37. Hu H., Voss J., Zhang G., Buchy P., Zuo T., Wang L., Wang F., Zhou F., Wang G., Tsai C., Calder L., Gamblin S.J., Zhang L., Deubel V., Zhou B., Skehel J.J., Zhou P. A human antibody recognizing a conserved epitope of H5 hemagglutinin broadly neutralizes highly pathogenic avian influenza H5N1 viruses. Journal of Virology 2012, 86(6):2978-2989.
38. Imai M., Watanabe T., Hatta M., Das S.C., Ozawa M., Shinya K., Zhong G., Hanson A., Katsura H., Watanabe S., Li C., Kawakami E., Yamada S., Kiso M., Suzuki Y., Maher E.A., Neumann G., Kawaoka Y. Experimental adaptation of an influenza H5 HA confers respiratory droplet transmission to a reassortant H5 HA/H1N1 virus in ferrets. Nature 2012, 486(7403):420-428.
39. Ito T., Suzuki Y., Mitnaul L., Vines A., Kida H., Kawaoka Y. Receptor specificity of influenza A viruses correlates with the agglutination of erythrocytes from different animal species. Virology 1997, 227(2):493-499.
40. Jackson S., Van Hoeven N., Chen L.M., Maines T.R., Cox N.J., Katz J.M., Donis R.O. Reassortment between avian H5N1 and human H3N2 influenza viruses in ferrets: a public health risk assessment. Journal of Virology 2009, 83(16):8131-8140.
41. Jameson J., Cruz J., Terajima M., Ennis F.A. Human CD8+ and CD4+ T lymphocyte memory to influenza A viruses of swine and avian species. Journal of Immunology 1999, 162(12):7578-7583.
42. Kandun I.N., Tresnaningsih E., Purba W.H., Lee V., Samaan G., Harun S., Soni E., Septiawati C., Setiawati T., Sariwati E., Wandra T. Factors associated with case fatality of human H5N1 virus infections in Indonesia: a case series. Lancet 2008, 372(9640):744-749.
43. Kashyap A.K., Steel J., Oner A.F., Dillon M.A., Swale R.E., Wall K.M., Perry K.J., Faynboym A., Ilhan M., Horowitz M., Horowitz L., Palese P., Bhatt R.R., Lerner R.A. Combinatorial antibody libraries from survivors of the Turkish H5N1 avian influenza outbreak reveal virus neutralization strategies. Proceedings of the National Academy of Sciences of the United States of America 2008, 105(16):5986-5991.
44. Kashyap A.K., Steel J., Rubrum A., Estelles A., Briante R., Ilyushina N.A., Xu L., Swale R.E., Faynboym A.M., Foreman P.K., Horowitz M., Horowitz L., Webby R., Palese P., Lerner R.A., Bhatt R.R. Protection from the 2009 H1N1 pandemic influenza by an antibody from combinatorial survivor-based libraries. PLoS Pathogens 2010, 6(7):e1000990.
45. Katz J.M., Hancock K., Xu X. Serologic assays for influenza surveillance, diagnosis and vaccine evaluation. Expert Review of Anti-infective Therapy 2011, 9(6):669-683.
46. Katz J.M., Lim W., Bridges C.B., Rowe T., Hu-Primmer J., Lu X., Abernathy R.A., Clarke M., Conn L., Kwong H., Lee M., Au G., Ho Y.Y., Mak K.H., Cox N.J., Fukuda K. Antibody response in individuals infected with avian influenza A (H5N1) viruses and detection of anti-H5 antibody among household and social contacts. The Journal of Infectious Diseases 1999, 180(6):1763-1770.
47. Katz J.M., Lu X., Frace A.M., Morken T., Zaki S.R., Tumpey T.M. Pathogenesis of and immunity to avian influenza A H5 viruses. Biomedicine and Pharmacotherapy 2000, 54(4):178-187.
48. Kaverin N.V., Rudneva I.A., Govorkova E.A., Timofeeva T.A., Shilov A.A., Kochergin-Nikitsky K.S., Krylov P.S., Webster R.G. Epitope mapping of the hemagglutinin molecule of a highly pathogenic H5N1 influenza virus by using monoclonal antibodies. Journal of Virology 2007, 81(23):12911-12917.
49. Khurana S., Sasono P., Fox A., Nguyen V.K., Le Q.M., Pham Q.T., Nguyen T.H., Nguyen T.L., Horby P., Golding H. H5N1-SeroDetect EIA and rapid test: a novel differential diagnostic assay for serodiagnosis of H5N1 infections and surveillance. Journal of Virology 2011, 85(23):12455-12463.
50. Khurana S., Suguitan A.L., Rivera Y., Simmons C.P., Lanzavecchia A., Sallusto F., Manischewitz J., King L.R., Subbarao K., Golding H. Antigenic fingerprinting of H5N1 avian influenza using convalescent sera and monoclonal antibodies reveals potential vaccine and diagnostic targets. PLoS Medicine 2009, 6(4):e1000049.
51. Killingley B., Enstone J., Booy R., Hayward A., Oxford J., Ferguson N., Nguyen Van-Tam J. Influenza transmission strategy development, g. Potential role of human challenge studies for investigation of influenza transmission. The Lancet Infectious Diseases 2011, 11(11):879-886.
52. Kreijtz J.H., Bodewes R., van den Brand J.M., de Mutsert G., Baas C., van Amerongen G., Fouchier R.A., Osterhaus A.D., Rimmelzwaan G.F. Infection of mice with a human influenza A/H3N2 virus induces protective immunity against lethal infection with influenza A/H5N1 virus. Vaccine 2009, 27(36):4983-4989.
53. Kreijtz J.H., de Mutsert G., van Baalen C.A., Fouchier R.A., Osterhaus A.D., Rimmelzwaan G.F. Cross-recognition of avian H5N1 influenza virus by human cytotoxic T-lymphocyte populations directed to human influenza A virus. Journal of Virology 2008, 82(11):5161-5166.
54. Lee L.Y., Ha do L.A., Simmons C., de Jong M.D., Chau N.V., Schumacher R., Peng Y.C., McMichael A.J., Farrar J.J., Smith G.L., Townsend A.R., Askonas B.A., Rowland-Jones S., Dong T. Memory T cells established by seasonal human influenza A infection cross-react with avian influenza A (H5N1) in healthy individuals. The Journal of Clinical Investigation 2008, 118(10):3478-3490.
55. Leroux-Roels I., Van der Wielen M., Kafeja F., Vandermeulen C., Lazarus R., Snape M.D., John T., Carre C., Nougarede N., Pepin S., Leroux-Roels G., Hoppenbrouwers K., Pollard A.J., Van Damme P. Humoral and cellular immune responses to split-virion H5N1 influenza vaccine in young and elderly adults. Vaccine 2009, 27(49):6918-6925.
56. Lipatov A.S., Kwon Y.K., Pantin-Jackwood M.J., Swayne D.E. Pathogenesis of H5N1 influenza virus infections in mice and ferret models differs according to respiratory tract or digestive system exposure. The Journal of Infectious Diseases 2009, 199(5):717-725.
57. Louisirirotchanakul S., Lerdsamran H., Wiriyarat W., Sangsiriwut K., Chaichoune K., Pooruk P., Songserm T., Kitphati R., Sawanpanyalert P., Komoltri C., Auewarakul P., Puthavathana P. Erythrocyte binding preference of avian influenza H5N1 viruses. Journal of Clinical Microbiology 2007, 45(7):2284-2286.
58. Lu X., Edwards L.E., Desheva J.A., Nguyen D.C., Rekstin A., Stephenson I., Szretter K., Cox N.J., Rudenko L.G., Klimov A., Katz J.M. Cross-protective immunity in mice induced by live-attenuated or inactivated vaccines against highly pathogenic influenza A (H5N1) viruses. Vaccine 2006, 24(44-46):6588-6593.
59. Maines T.R., Chen L.M., Matsuoka Y., Chen H., Rowe T., Ortin J., Falcon A., Nguyen T.H., Mai le Q., Sedyaningsih E.R., Harun S., Tumpey T.M., Donis R.O., Cox N.J., Subbarao K., Katz J.M. Lack of transmission of H5N1 avian-human reassortant influenza viruses in a ferret model. Proceedings of the National Academy of Sciences of the United States of America 2006, 103(32):12121-12126.
60. Maines T.R., Lu X.H., Erb S.M., Edwards L., Guarner J., Greer P.W., Nguyen D.C., Szretter K.J., Chen L.M., Thawatsupha P., Chittaganpitch M., Waicharoen S., Nguyen D.T., Nguyen T., Nguyen H.H., Kim J.H., Hoang L.T., Kang C., Phuong L.S., Lim W., Zaki S., Donis R.O., Cox N.J., Katz J.M., Tumpey T.M. Avian influenza (H5N1) viruses isolated from humans in Asia in 2004 exhibit increased virulence in mammals. Journal of Virology 2005, 79(18):11788-11800.
61. Middleton D., Rockman S., Pearse M., Barr I., Lowther S., Klippel J., Ryan D., Brown L. Evaluation of vaccines for H5N1 influenza virus in ferrets reveals the potential for protective single-shot immunization. Journal of Virology 2009, 83(15):7770-7778.
62. Miller E., Hoschler K., Hardelid P., Stanford E., Andrews N., Zambon M. Incidence of 2009 pandemic influenza A H1N1 infection in England: a cross-sectional serological study. Lancet 2010, 375(9720):1100-1108.
63. Mounts A.W., Kwong H., Izurieta H.S., Ho Y., Au T., Lee M., Buxton Bridges C., Williams S.W., Mak K.H., Katz J.M., Thompson W.W., Cox N.J., Fukuda K. Case-control study of risk factors for avian influenza A (H5N1) disease, Hong Kong, 1997. The Journal of Infectious Diseases 1999, 180(2):505-508.
64. Murphy B.R., Chalhub E.G., Nusinoff S.R., Kasel J., Chanock R.M. Temperature-sensitive mutants of influenza virus. 3. Further characterization of the ts-1(E) influenza A recombinant (H3N2) virus in man. The Journal of Infectious Diseases 1973, 128(4):479-487.
65. Murphy B.R., Kasel J.A., Chanock R.M. Association of serum anti-neuraminidase antibody with resistance to influenza in man. The New England Journal of Medicine 1972, 286(25):1329-1332.
66. Nefkens I., Garcia J.M., Ling C.S., Lagarde N., Nicholls J., Tang D.J., Peiris M., Buchy P., Altmeyer R. Hemagglutinin pseudotyped lentiviral particles: characterization of a new method for avian H5N1 influenza sero-diagnosis. Journal of Clinical Virology 2007, 39(1):27-33.
67. O'Neill E., Krauss S.L., Riberdy J.M., Webster R.G., Woodland D.L. Heterologous protection against lethal A/HongKong/156/97 (H5N1) influenza virus infection in C57BL/6 mice. The Journal of General Virology 2000, 81(Pt 11):2689-2696.
68. Palladino G., Mozdzanowska K., Washko G., Gerhard W. Virus-neutralizing antibodies of immunoglobulin G (IgG) but not of IgM or IgA isotypes can cure influenza virus pneumonia in SCID mice. Journal of Virology 1995, 69(4):2075-2081.
69. Powell T.J., Fox A., Peng Y., Quynh Mai le T., Lien V.T., Hang N.L., Wang L., Lee L.Y., Simmons C.P., McMichael A.J., Farrar J.J., Askonas B.A., Duong T.N., Thai P.Q., Thu Yen N.T., Rowland-Jones S.L., Hien N.T., Horby P., Dong T. Identification of H5N1-specific T-cell responses in a high-risk cohort in vietnam indicates the existence of potential asymptomatic infections. The Journal of Infectious Diseases 2012, 205(1):20-27.
70. Richards K.A., Chaves F.A., Sant A.J. Infection of HLA-DR1 transgenic mice with a human isolate of influenza a virus (H1N1) primes a diverse CD4 T-cell repertoire that includes CD4 T cells with heterosubtypic cross-reactivity to avian (H5N1) influenza virus. Journal of Virology 2009, 83(13):6566-6577.
71. Rimmelzwaan G.F., McElhaney J.E. Correlates of protection: novel generations of influenza vaccines. Vaccine 2008, 26(Suppl. 4):D41-D44.
72. Roti M., Yang J., Berger D., Huston L., James E.A., Kwok W.W. Healthy human subjects have CD4+ T cells directed against H5N1 influenza virus. Journal of Immunology 2008, 180(3):1758-1768.
73. Rowe T., Abernathy R.A., Hu-Primmer J., Thompson W.W., Lu X., Lim W., Fukuda K., Cox N.J., Katz J.M. Detection of antibody to avian influenza A (H5N1) virus in human serum by using a combination of serologic assays. Journal of Clinical Microbiology 1999, 37(4):937-943.
74. Sandbulte M.R., Jimenez G.S., Boon A.C., Smith L.R., Treanor J.J., Webby R.J. Cross-reactive neuraminidase antibodies afford partial protection against H5N1 in mice and are present in unexposed humans. PLoS Medicine 2007, 4(2):e59.
75. Sasaki S., Jaimes M.C., Holmes T.H., Dekker C.L., Mahmood K., Kemble G.W., Arvin A.M., Greenberg H.B. Comparison of the influenza virus-specific effector and memory B-cell responses to immunization of children and adults with live attenuated or inactivated influenza virus vaccines. Journal of Virology 2007, 81(1):215-228.
76. Shoji Y., Chichester J.A., Palmer G.A., Farrance C.E., Stevens R., Stewart M., Goldschmidt L., Deyde V., Gubareva L., Klimov A., Mett V., Yusibov V. An influenza N1 neuraminidase-specific monoclonal antibody with broad neuraminidase inhibition activity against H5N1 HPAI viruses. Human Vaccines 2011, 7:199-204.
77. Simmons C.P., Bernasconi N.L., Suguitan A.L., Mills K., Ward J.M., Chau N.V., Hien T.T., Sallusto F., Ha do Q., Farrar J., de Jong M.D., Lanzavecchia A., Subbarao K. Prophylactic and therapeutic efficacy of human monoclonal antibodies against H5N1 influenza. PLoS Medicine 2007, 4(5):e178.
78. Smallman-Raynor M., Cliff A.D. Avian influenza A (H5N1) age distribution in humans. Emerging Infectious Diseases 2007, 13(3):510-512.
79. Stephenson I., Heath A., Major D., Newman R.W., Hoschler K., Junzi W., Katz J.M., Weir J.P., Zambon M.C., Wood J.M. Reproducibility of serologic assays for influenza virus A (H5N1). Emerging Infectious Diseases 2009, 15(8):1252-1259.
80. Stephenson I., Wood J.M., Nicholson K.G., Charlett A., Zambon M.C. Detection of anti-H5 responses in human sera by HI using horse erythrocytes following MF59-adjuvanted influenza A/Duck/Singapore/97 vaccine. Virus Research 2004, 103(1/2):91-95.
81. Stephenson I., Wood J.M., Nicholson K.G., Zambon M.C. Sialic acid receptor specificity on erythrocytes affects detection of antibody to avian influenza haemagglutinin. Journal of Medical Virology 2003, 70(3):391-398.
82. Sui J., Hwang W.C., Perez S., Wei G., Aird D., Chen L.M., Santelli E., Stec B., Cadwell G., Ali M., Wan H., Murakami A., Yammanuru A., Han T., Cox N.J., Bankston L.A., Donis R.O., Liddington R.C., Marasco W.A. Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses. Nature Structural & Molecular Biology 2009, 16(3):265-273.
83. Sun L., Lu X., Li C., Wang M., Liu Q., Li Z., Hu X., Li J., Liu F., Li Q., Belser J.A., Hancock K., Shu Y., Katz J.M., Liang M., Li D. Generation, characterization and epitope mapping of two neutralizing and protective human recombinant antibodies against influenza A H5N1 viruses. PLoS ONE 2009, 4(5):e5476.
84. Temperton N.J., Hoschler K., Major D., Nicolson C., Manvell R., Hien V.M., Ha do Q., de Jong M., Zambon M., Takeuchi Y., Weiss R.A. A sensitive retroviral pseudotype assay for influenza H5N1-neutralizing antibodies. Influenza and Other Respiratory Viruses 2007, 1(3):105-112.
85. Thomson C.A., Wang Y., Jackson L.M., Olson M., Wang W., Liavonchanka A., Keleta L., Silva V., Diederich S., Jones R.B., Gubbay J., Pasick J., Petric M., Jean F., Allen V.G., Brown E.G., Rini J.M., Schrader J.W. Pandemic H1N1 Influenza Infection and Vaccination in Humans Induces Cross-Protective Antibodies that Target the Hemagglutinin Stem. Frontiers in Immunology 2012, 3:87.
86. Tompkins S.M., Zhao Z.S., Lo C.Y., Misplon J.A., Liu T., Ye Z., Hogan R.J., Wu Z., Benton K.A., Tumpey T.M., Epstein S.L. Matrix protein 2 vaccination and protection against influenza viruses, including subtype H5N1. Emerging Infectious Diseases 2007, 13(3):426-435.
87. Tumpey T.M., Lu X., Morken T., Zaki S.R., Katz J.M. Depletion of lymphocytes and diminished cytokine production in mice infected with a highly virulent influenza A (H5N1) virus isolated from humans. Journal of Virology 2000, 74(13):6105-6116.
88. Ungchusak K., Auewarakul P., Dowell S.F., Kitphati R., Auwanit W., Puthavathana P., Uiprasertkul M., Boonnak K., Pittayawonganon C., Cox N.J., Zaki S.R., Thawatsupha P., Chittaganpitch M., Khontong R., Simmerman J.M., Chunsutthiwat S. Probable person-to-person transmission of avian influenza A (H5N1). The New England Journal of Medicine 2005, 352(4):333-340.
89. Uyeki T.M. Human infection with highly pathogenic avian influenza A (H5N1) virus: review of clinical issues. Clinical Infectious Diseases 2009, 49(2):279-290.
90. Van Kerkhove M.D., Mumford E., Mounts A.W., Bresee J., Ly S., Bridges C.B., Otte J. Highly pathogenic avian influenza (H5N1): pathways of exposure at the animal-human interface, a systematic review. PLoS ONE 2011, 6(1):e14582.
91. Veguilla V., Hancock K., Schiffer J., Gargiullo P., Lu X., Aranio D., Branch A., Dong L., Holiday C., Liu F., Steward-Clark E., Sun H., Tsang B., Wang D., Whaley M., Bai Y., Cronin L., Browning P., Dababneh H., Noland H., Thomas L., Foster L., Quinn C.P., Soroka S.D., Katz J.M. Sensitivity and specificity of serologic assays for detection of human infection with 2009 pandemic H1N1 virus in U.S. populations. Journal of Clinical Microbiology 2011, 49(6):2210-2215.
92. Wang H., Feng Z., Shu Y., Yu H., Zhou L., Zu R., Huai Y., Dong J., Bao C., Wen L., Wang H., Yang P., Zhao W., Dong L., Zhou M., Liao Q., Yang H., Wang M., Lu X., Shi Z., Wang W., Gu L., Zhu F., Li Q., Yin W., Yang W., Li D., Uyeki T.M., Wang Y. Probable limited person-to-person transmission of highly pathogenic avian influenza A (H5N1) virus in China. Lancet 2008, 371(9622):1427-1434.
93. Wang R., Song A., Levin J., Dennis D., Zhang N.J., Yoshida H., Koriazova L., Madura L., Shapiro L., Matsumoto A., Yoshida H., Mikayama T., Kubo R.T., Sarawar S., Cheroutre H., Kato S. Therapeutic potential of a fully human monoclonal antibody against influenza A virus M2 protein. Antiviral Research 2008, 80(2):168-177.
94. Wang W., Butler E.N., Veguilla V., Vassell R., Thomas J.T., Moos M., Ye Z., Hancock K., Weiss C.D. Establishment of retroviral pseudotypes with influenza hemagglutinins from H1, H3, and H5 subtypes for sensitive and specific detection of neutralizing antibodies. Journal of Virology Methods 2008, 153(2):111-119.
95. Wang X., Chan C.C., Yang M., Deng J., Poon V.K., Leung V.H., Ko K.H., Zhou J., Yuen K.Y., Zheng B.J., Lu L. A critical role of IL-17 in modulating the B-cell response during H5N1 influenza virus infection. Cellular & Molecular Immunology 2011, 8(6):462-468.
96. WHO Manual for Laboratory Diagnosis and Virological Surveillance of Influenza 2011.
97. WHO Update on human cases of highly pathogenic avian influenza A(H5N1) virus infection, 2011. Weekly Epidemiological Record 2012, 87(13):117-128.
98. WHO/OIE/FAO H.N.E.W.G. Continued evolution of highly pathogenic avian influenza A (H5N1): updated nomenclature. Influenza and Other Respiratory Viruses 2012, 6(1):1-5.
99. Wiley D.C., Wilson I.A., Skehel J.J. Structural identification of the antibody-binding sites of Hong Kong influenza haemagglutinin and their involvement in antigenic variation. Nature 1981, 289(5796):373-378.
100. Wilkinson T.M., Li C.K., Chui C.S., Huang A.K., Perkins M., Liebner J.C., Lambkin-Williams R., Gilbert A., Oxford J., Nicholas B., Staples K.J., Dong T., Douek D.C., McMichael A.J., Xu X.N. Preexisting influenza-specific CD4+ T cells correlate with disease protection against influenza challenge in humans. Nature Medicine 2012, 18(2):274-280.
101. Wright P.F., Ross K.B., Thompson J., Karzon D.T. Influenza A infections in young children. Primary natural infection and protective efficacy of live-vaccine-induced or naturally acquired immunity. The New England Journal of Medicine 1977, 296(15):829-834.
102. Ye J., Shao H., Hickman D., Angel M., Xu K., Cai Y., Song H., Fouchier R.A., Qin A., Perez D.R. Intranasal delivery of an IgA monoclonal antibody effective against sublethal H5N1 influenza virus infection in mice. Clinical and Vaccine Immunology 2010, 17(9):1363-1370.
103. Zhou L., Liao Q., Dong L., Huai Y., Bai T., Xiang N., Shu Y., Liu W., Wang S., Qin P., Wang M., Xing X., Lv J., Chen R.Y., Feng Z., Yang W., Uyeki T.M., Yu H. Risk factors for human illness with avian influenza A (H5N1) virus infection in China. The Journal of Infectious Diseases 2009, 199(12):1726-1734.